About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Experience Knolens
Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBD
Vial, a clinical-stage biotechnology company, announced the first-in-human dosing of its novel, subcutaneous, half-life extended monoclonal antibody t...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Vial Initiates Phase 1 Trial of Subcutaneous Half-Life Extended Anti-TL1A Antibody for IBD